Published online January 2, 2008
PEDIATRICS Vol. 121 Supplement January 2008, pp. S96 (doi:10.1542/peds.2007-2022S)
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ogino, H.
Right arrow Articles by Yanagawa, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ogino, H.
Right arrow Articles by Yanagawa, H.

ALLERGOLOGY


STRATEGY FOR HIGH-DOSE IMMUNOGLOBULIN THERAPY–RESISTANT KAWASAKI DISEASE: CURRENT STATUS IN JAPAN

Hirotaro Oginoa, Yosikazu Nakamurab, Mayumi Yashirob and Hiroshi Yanagawac

a Department of Pediatrics, Otokoyama Hospital, Kansai Medical University, Osaka, Japan
b Department of Public Health, Jichi Medical University, Tochigi, Japan
c Saitama Prefectural University, Saitama, Japan

ABSTRACT

INTRODUCTION: High-dose intravenous immunoglobulin (IVIg) therapy has decreased the risk for development of coronary arterial lesions (CALs) in Kawasaki disease (KD), whereas patients who show resistance to IVIg have a higher risk for CALs.

OBJECTIVE: The purpose of this study was to determine the risk for CALs in patients with IVIg-resistant KD and to investigate whether an additional therapy might affect its risk, based on the nationwide survey (2003–2004) in Japan.

METHODS: Information from 11 510 children with KD treated with IVIg with the first 9 days of illness was available. The incidence of CALs was compared among 4 groups: group 1 (G1), children who responded to initial IVIg; group 2 (G2), IVIg-resistant patients who received additional IVIg; group 3 (G3), IVIg-resistant patients who received additional prednisolone (PSL); and group 4 (G4), IVIg-resistant patients who received additional IVIg plus PSL. CALs were assessed on the 30th day of illness.

RESULTS: Among 11 510 cases, 2229 patients (19.4%) were resistant to initial IVIg treatment and received additional therapy. The incidence of CALs was significantly lower in children who responded to IVIg (G1, n = 9281) than in those with IVIg resistance (1.87% and 11.03%, respectively). In each of the additional therapy groups, the incidences of CALs were as follows: G2 (n = 1108), 6.68%; G3 (n = 93), 9.68%; and G4 (n = 135), 22.22%. Thus, the risk for development of CALs was significantly higher for patients in G4 than those in G1 and G2.

CONCLUSIONS: Additional therapy including PSL may increase the risk for CALs; however, several selection biases, such as more severe cases in G3 and G4, might have affected the results.

Submitted by Hirotaro Ogino